About this trial

The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's treatment.

Primary Objective

To provide expanded access to L-\[11C\]methionine as a positron-emitting tracer in children and young adults for the positron emission tomography (PET) imaging of neoplasms of the central nervous system (CNS) and head and neck to guide therapeutic management of disease.

Eligibility criteria

Qualifiers

All participants under the care of a SJCRH physician with known or suspected neoplastic disease of the CNS or head and neck are eligible for participation.

No limit on age.

Patients of all genders and all ethnic groups under the care of a SJCRH physician.

Female participants of child-bearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.

Disqualifiers

More than six L-[11C]methionine PET scans within the previous 12 months.

Inability or willingness of patient, parent, or guardian to consent.

Trial design

Treatments tested in this trial

  • L-(11C) methionine

Treatment groups

No treatment groups listed

Locations

1
St. Jude Children's Research Hospital38105, MemphisTennessee, United States

Sponsors and collaborators

St. Jude Children's Research Hospital

Lead sponsor